Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / COVID-19 - Page 26

COVID-19

Vaccines still effective against Delta variant of concern, says Oxford-led study of the COVID-19 Infections Survey
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine

Vaccines still effective against Delta variant of concern, says Oxford-led study of the COVID-19 Infections Survey

On Aug. 19, 2021, the University of Oxford reported that obtaining two vaccine doses remained the most effective…

Read More Vaccines still effective against Delta variant of concern, says Oxford-led study of the COVID-19 Infections SurveyContinue

Researchers developed COVID-19 severity screening method based on the Agilent Cary 630 FTIR spectrometer
COVID-19 | Life Science History

Researchers developed COVID-19 severity screening method based on the Agilent Cary 630 FTIR spectrometer

On Aug. 18, 2021, Agilent Technologies announced that researchers at the Indian Institute of Technology Bombay in India…

Read More Researchers developed COVID-19 severity screening method based on the Agilent Cary 630 FTIR spectrometerContinue

NIH study showed no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms
COVID-19 | Life Science History

NIH study showed no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms

On Aug. 18, 2021, the final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO)…

Read More NIH study showed no significant benefit of convalescent plasma for COVID-19 outpatients with early symptomsContinue

Antibodies elicited by COVID-19 vaccination effective against delta variant
COVID-19 | Therapeutics | Vaccine

Antibodies elicited by COVID-19 vaccination effective against delta variant

On Aug. 17, 2021, researchers reported the delta variant of the virus that causes COVID-19 was not particularly…

Read More Antibodies elicited by COVID-19 vaccination effective against delta variantContinue

NIH scientists developed faster COVID-19 test
COVID-19 | Life Science History | NIH

NIH scientists developed faster COVID-19 test

On Aug. 16, 2021, scientists at the National Institutes of Health (NIH) announced they had developed a new…

Read More NIH scientists developed faster COVID-19 testContinue

Moderna announced supply agreement with Canada for expanded supply of COVID-19 Vaccine from 2022 – 2024
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced supply agreement with Canada for expanded supply of COVID-19 Vaccine from 2022 – 2024

On Aug. 16, 2021, Moderna announced a revised supply agreement with the Government of Canada for up to…

Read More Moderna announced supply agreement with Canada for expanded supply of COVID-19 Vaccine from 2022 – 2024Continue

Pfizer and BioNTech announced submission of initial data to FDA to support booster dose of COVID-19 vaccine
COVID-19 | FDA | Life Science History

Pfizer and BioNTech announced submission of initial data to FDA to support booster dose of COVID-19 vaccine

On Aug. 16, 2021, Pfizer and BioNTech announced that they had submitted Phase 1 data to the U.S….

Read More Pfizer and BioNTech announced submission of initial data to FDA to support booster dose of COVID-19 vaccineContinue

FDA declined to issue Rigel Pharma EUA for fostamatinib for teatment of COVID-19 in hospitalized adults
COVID-19 | FDA | Life Science History | NIH

FDA declined to issue Rigel Pharma EUA for fostamatinib for teatment of COVID-19 in hospitalized adults

On Aug. 13, 2021, Rigel Pharma announced that the U.S. Food and Drug Administration (FDA) had informed the…

Read More FDA declined to issue Rigel Pharma EUA for fostamatinib for teatment of COVID-19 in hospitalized adultsContinue

Moderna announced FDA authorization of third dose of COVID-19 vaccine for immunocompromised individuals
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Moderna announced FDA authorization of third dose of COVID-19 vaccine for immunocompromised individuals

On Aug. 13, 2021, Moderna announced that the Food and Drug Administration (FDA) had approved an update to…

Read More Moderna announced FDA authorization of third dose of COVID-19 vaccine for immunocompromised individualsContinue

The Department of Veterans Affairs expanded mandate for COVID-19 vaccines among VHA employees
Biotechnology | COVID-19 | Infectious Disease | Vaccine

The Department of Veterans Affairs expanded mandate for COVID-19 vaccines among VHA employees

On Aug. 12, 2021, the U.S. Department of Veterans Affairs (VA) announced that it expanded his previous COVID-19…

Read More The Department of Veterans Affairs expanded mandate for COVID-19 vaccines among VHA employeesContinue

Moderna announced study showing Its COVID-19 vaccine maintained antibodies against variants of concern
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced study showing Its COVID-19 vaccine maintained antibodies against variants of concern

On Aug. 12, 2021, Moderna announced the publication of new data on the durability of the Moderna COVID-19…

Read More Moderna announced study showing Its COVID-19 vaccine maintained antibodies against variants of concernContinue

Innovation Pharmaceuticals’ phase 2 clinical trial of Brilacidin for COVID-19 trial database under review in preparation for lock
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics

Innovation Pharmaceuticals’ phase 2 clinical trial of Brilacidin for COVID-19 trial database under review in preparation for lock

On Aug. 12, 2021, Innovation Pharma released information regarding the status of its randomized, double-blind, placebo-controlled Phase 2…

Read More Innovation Pharmaceuticals’ phase 2 clinical trial of Brilacidin for COVID-19 trial database under review in preparation for lockContinue

WHO’s Solidarity clinical trial entered a new phase with three new candidate drugs
COVID-19 | Therapeutics | WHO

WHO’s Solidarity clinical trial entered a new phase with three new candidate drugs

On Aug. 11, 2021, the World Health Organization (WHO) announced the next phase in its Solidarity trial that…

Read More WHO’s Solidarity clinical trial entered a new phase with three new candidate drugsContinue

NIH launched study of third COVID-19 vaccine dose in kidney transplant recipients
Biotechnology | COVID-19 | Infectious Disease | Life Science History | NIH | Vaccine

NIH launched study of third COVID-19 vaccine dose in kidney transplant recipients

On Aug. 10, 2021, the National Institutes of Health (NIH) announced that a pilot study had begun to…

Read More NIH launched study of third COVID-19 vaccine dose in kidney transplant recipientsContinue

Cardinal Health partnered with Abbott and Quidel to offer rapid OTC COVID-19 tests
COVID-19 | Life Science History

Cardinal Health partnered with Abbott and Quidel to offer rapid OTC COVID-19 tests

On Aug. 10, 2021, Cardinal Health announced its efforts to commercialize and broaden access to over-the-counter rapid COVID-19…

Read More Cardinal Health partnered with Abbott and Quidel to offer rapid OTC COVID-19 testsContinue

Australian Therapeutic Goods Administration granted provisional registration for Moderna’s COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Australian Therapeutic Goods Administration granted provisional registration for Moderna’s COVID-19 vaccine

On Aug. 9, 2021, Moderna announced that the Therapeutic Goods Administration (TGA) had granted provisional registration to the…

Read More Australian Therapeutic Goods Administration granted provisional registration for Moderna’s COVID-19 vaccineContinue

INOVIO and Advaccine receive regulatory allowance for prime-boost clinical trials in China using INO-4800, COVID-19 DNA vaccine candidate
Biotechnology | COVID-19 | Infectious Disease | Vaccine

INOVIO and Advaccine receive regulatory allowance for prime-boost clinical trials in China using INO-4800, COVID-19 DNA vaccine candidate

On Aug. 9, 2021, Inovio Pharma announced that it had received regulatory allowance for two clinical trials investigating…

Read More INOVIO and Advaccine receive regulatory allowance for prime-boost clinical trials in China using INO-4800, COVID-19 DNA vaccine candidateContinue

CDC reported vaccination offers higher protection than previous COVID-19 infection
CDC | COVID-19 | Life Science History

CDC reported vaccination offers higher protection than previous COVID-19 infection

On Aug. 6, 2021, the Centers for Disease Control and Prevention (CDC) annouced in MMWR that a study…

Read More CDC reported vaccination offers higher protection than previous COVID-19 infectionContinue

Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody

On Aug. 5, 2021, Novavax announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle…

Read More Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibodyContinue

Lenzilumab treatment may provide enhanced likelihood of survival without ventilation in hospitalized black and African-American COVID-19 patients
COVID-19 | Life Science History

Lenzilumab treatment may provide enhanced likelihood of survival without ventilation in hospitalized black and African-American COVID-19 patients

On Aug. 4, 2021, Humanigen announced analysis of results from its Phase 3 LIVE-AIR study of lenzilumab in…

Read More Lenzilumab treatment may provide enhanced likelihood of survival without ventilation in hospitalized black and African-American COVID-19 patientsContinue

Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine

On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…

Read More Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccineContinue

NEJM published positive phase 3 trial results for REGEN-COV to prevent SARS-CoV-2 infection
Biotechnology | COVID-19

NEJM published positive phase 3 trial results for REGEN-COV to prevent SARS-CoV-2 infection

On Aug. 4, 2021, Regeneron announced that the New England Journal of Medicine (NEJM) had published positive detailed…

Read More NEJM published positive phase 3 trial results for REGEN-COV to prevent SARS-CoV-2 infectionContinue

INOVIO dosed first participant in phase 2 trial for its DNA vaccine against MERS, a Coronavirus Disease
Biotechnology | COVID-19 | Vaccine

INOVIO dosed first participant in phase 2 trial for its DNA vaccine against MERS, a Coronavirus Disease

On Aug. 4, 2021, Inovio Pharma announced that the company had dosed the first Phase 2 trial subject…

Read More INOVIO dosed first participant in phase 2 trial for its DNA vaccine against MERS, a Coronavirus DiseaseContinue

Vanda closed enrollment in ODYSSEY study comparing tradipitant and placebo In COVID-19 pneumonia patients
COVID-19 | Life Science History

Vanda closed enrollment in ODYSSEY study comparing tradipitant and placebo In COVID-19 pneumonia patients

On Aug. 3, 2021, Vanda Pharmaceuticals announced that enrollment had closed in the ODYSSEY study comparing tradipitant and…

Read More Vanda closed enrollment in ODYSSEY study comparing tradipitant and placebo In COVID-19 pneumonia patientsContinue

Illumina donated US $1 Million in sequencing capabilities for COVID-19 genomic surveillance in India
COVID-19 | Diagnostics | Genomics

Illumina donated US $1 Million in sequencing capabilities for COVID-19 genomic surveillance in India

On Aug. 3, 2021, Illumina announced it had donated US $1 million in sequencing capabilities to the Molecular…

Read More Illumina donated US $1 Million in sequencing capabilities for COVID-19 genomic surveillance in IndiaContinue

Lilly and Incyte’s baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
COVID-19 | Life Science History

Lilly and Incyte’s baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation

On Aug. 3, 2021, Eli Lilly and Incyte announced results from an additional cohort of 101 adult patients…

Read More Lilly and Incyte’s baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilationContinue

CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patients
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patients

On Aug. 3, 2021, CytoDyn announced that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved…

Read More CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patientsContinue

MPP, WHO, AFRIGEN, BIOVAC, SAMRC and Africa CDC announced LOI for tech transfer hub in South Africa
COVID-19 | Life Science History | Vaccine

MPP, WHO, AFRIGEN, BIOVAC, SAMRC and Africa CDC announced LOI for tech transfer hub in South Africa

On Jul. 30, 2021, the Medicines Patent Pool and the World Health Organization, Afrigen Biologics, the Biologicals and…

Read More MPP, WHO, AFRIGEN, BIOVAC, SAMRC and Africa CDC announced LOI for tech transfer hub in South AfricaContinue

FDA expanded authorized use of REGEN-COVル (casirivimab and imdevimab)
COVID-19 | FDA | Life Science History

FDA expanded authorized use of REGEN-COVル (casirivimab and imdevimab)

On Jul. 30, 2021, Regeneron announced that the FDA had updated the Emergency Use Authorization (EUA) for the…

Read More FDA expanded authorized use of REGEN-COVル (casirivimab and imdevimab)Continue

FDA broadened existing EUA of Lilly and Incyte’s baricitinib in patients hospitalized with COVID-19
COVID-19 | FDA | Therapeutics

FDA broadened existing EUA of Lilly and Incyte’s baricitinib in patients hospitalized with COVID-19

On Jul. 29, 2021, Incyte announced the U.S. Food and Drug Administration (FDA) had broadened the Emergency Use…

Read More FDA broadened existing EUA of Lilly and Incyte’s baricitinib in patients hospitalized with COVID-19Continue

Page navigation

Previous PagePrevious 1 … 24 25 26 27 28 … 98 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Clinical Research
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search